Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

This study tests a combination of becotatug vedotin (an antibody-drug conjugate that delivers chemotherapy directly to cancer cells) plus sintilimab (an immunotherapy that helps the immune system attack cancer) together with standard chemotherapy and radiation for patients with locally advanced nasopharyngeal carcinoma (a type of throat cancer at the back of the nasal passage). **You may be eligible if...** - You are between 18 and 70 years old - You have been confirmed to have a specific type of nasopharyngeal carcinoma (WHO type II or III) - Your cancer is locally advanced (involving nearby lymph nodes) without distant spread - You have not received any prior radiotherapy or chemotherapy for this cancer - Your blood counts, liver, and kidney function meet minimum requirements **You may NOT be eligible if...** - Your cancer has recurred or spread to distant organs - Your cancer is the keratinizing type (WHO type I) - You have active hepatitis B (with high viral load), active hepatitis C, or HIV - You have an active autoimmune disease requiring systemic treatment - You are pregnant or breastfeeding - You have had another cancer in the past 5 years (with some exceptions) Talk to your doctor to see if this trial is right for you.